Grant: Operating Grant - PA: IMHA - New Investigator - Skin Health Bridge Funding
Université Laval
$100,000.00
Tissue-engineered in-vitro skin model to facilitate the identification of disease biomarkers for Amyotrophic Lateral Sclerosis
FY 2014-15
Summary
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a complex genetic disease of the motor neurons, the nerve cells that control voluntary muscle movement. For unknown reasons, motor neurons die and the innervated muscles they control become weak and paralyzed. Death, usually from respiratory complications, typically occurs between three and five years after diagnosis. ALS is a devastating and rapidly fatal disease with currently only one available modestly effective treatment. Formal diagnosis of ALS is based on clinical assessment of related symptoms, which are appearing only late in the disease course after degeneration of a significant number of motor neurons. As a result, the identification and development of disease-modifying therapies is difficult. Novel strategies for early diagnosis, to monitor disease progression and to assess response to existing and future treatments are thus urgently needed. Interestingly, many skin changes that often precede the onset of neurological symptoms have been repeatedly reported in ALS patients, but never as yet fully explained due to lack of proper model allowing direct analysis at the histological, the biochemical and the molecular levels to confirm and validate results. Our hypothesis is that ALS-specific skin changes can be detected in patient-derived tissue-engineered skin (TES), which could be used to facilitate the identification of biomarkers. In contrast to the limited size of skin biopsies, the use of TES, generated in a culture dish and derived directly from patients, offers a renewable source of human tissue that will be needed for full data validation and for the identification of clinically useful biomarkers and identification of new therapeutics. This new model will therefore allow us to perform a variety of different tests and comprehensive analysis using the same skin substitute throughout experiments in order to better understand this interesting relation between skin changes and ALS.
Department
Program
Operating Grant - PA: IMHA - New Investigator - Skin Health Bridge Funding
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
329765
Name
Gros-Louis Francois
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Biomedical Engineering
Projecttitle
Tissue-engineered in-vitro skin model to facilitate the identification of disease biomarkers for Amyotrophic Lateral Sclerosis
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: IMHA - New Investigator - Skin Health Bridge Funding
Keyworddelim
Amyotrophic Lateral Sclerosis; Biomarker; Cell Line; Drug Screening; Infrared Spectroscopy; Skin Model; Tdp-43; Tissue-Engineering
Abstract
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a complex genetic disease of the motor neurons, the nerve cells that control voluntary muscle movement. For unknown reasons, motor neurons die and the innervated muscles they control become weak and paralyzed. Death, usually from respiratory complications, typically occurs between three and five years after diagnosis. ALS is a devastating and rapidly fatal disease with currently only one available modestly effective treatment. Formal diagnosis of ALS is based on clinical assessment of related symptoms, which are appearing only late in the disease course after degeneration of a significant number of motor neurons. As a result, the identification and development of disease-modifying therapies is difficult. Novel strategies for early diagnosis, to monitor disease progression and to assess response to existing and future treatments are thus urgently needed. Interestingly, many skin changes that often precede the onset of neurological symptoms have been repeatedly reported in ALS patients, but never as yet fully explained due to lack of proper model allowing direct analysis at the histological, the biochemical and the molecular levels to confirm and validate results. Our hypothesis is that ALS-specific skin changes can be detected in patient-derived tissue-engineered skin (TES), which could be used to facilitate the identification of biomarkers. In contrast to the limited size of skin biopsies, the use of TES, generated in a culture dish and derived directly from patients, offers a renewable source of human tissue that will be needed for full data validation and for the identification of clinically useful biomarkers and identification of new therapeutics. This new model will therefore allow us to perform a variety of different tests and comprehensive analysis using the same skin substitute throughout experiments in order to better understand this interesting relation between skin changes and ALS.
Competitiondate
201503
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gros-Louis, Francois
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~